Skip to main content
. 2021 Aug 9;2021:1412663. doi: 10.1155/2021/1412663

Table 1.

Characteristics of Crohn's disease patients.

  Results (n = 122) Non-5-ASA (n = 30) 5-ASA (n = 92) P value
Age, median (IQR) 33.0 (26.0–46.0) 32.5 (20.5–40.3) 33.5 (28.0–46.0) 0.082
Age at diagnosis, median (IQR) 27.0 (21.0–40.0) 28.0 (16.0–39.0) 27.0 (22.0–41.8) 0.184
Female, n (%) 50 (41.0) 12 (40.0) 38 (41.3) 0.900
Smoking, n (%)       0.330
 Never 95 (77.9) 25 (83.3) 70 (76.1)  
 Former 2 (1.6) 1 (3.3) 1 (1.1)  
 Current 25 (20.5) 4 (13.3) 21 (22.8)  
Age at diagnosis, n (%)       0.070
 A1 17 (13.9) 8 (26.7) 9 (9.8)  
 A2 76 (62.3) 17 (56.7) 59 (64.1)  
 A3 29 (23.8) 5 (16.7) 24 (26.1)  
Location at diagnosis, n (%)       0.753
 L1 24 (19.7) 5 (16.7) 19 (20.7)  
 L2 50 (41.0) 14 (46.7) 36 (39.1)  
 L3 48 (39.3) 11 (36.7) 37 (40.2)  
 L4 involvement 8 (6.6) 3 (10.0) 2 (2.2) 0.095
Behaviour at diagnosis, n (%)       0.403
 B1 87 (71.3) 23 (76.7) 64 (69.6)  
 B2 30 (24.6) 5 (16.7) 25 (27.2)  
 B3 5 (4.1) 2 (6.7) 3 (3.3)  
Perianal disease at diagnosis, n (%) 5 (4.1) 1 (3.3) 4 (4.3) 1.000
Appendicectomy, n (%) 31 (25.4) 8 (26.7) 23 (25.0) 0.856
Elevated ESR at diagnosis, n (%) 73 (59.8) 19 (63.3) 54 (58.7) 0.653
CDAI at diagnosis, median (IQR) 171.0 (102.0–259.5) 161.0 (100.0–342.0) 173.0 (102.0–246.0) 0.562
Cumulative exposures for treatment, n (%)        
 5-Aminosalicylic acid 92 (75.4) — — —
 Corticosteroid 68 (55.7) 15 (50.0) 53 (57.6) 0.466
 Immunomodulators 64 (52.5) 13 (43.3) 51 (55.4) 0.249
 Biologics 70 (57.4) 18 (60.0) 52 (56.5) 0.738

IQR, interquartile range; ESR, erythrocyte sedimentation rate; CDAI: Crohn's disease activity index; 5-ASA, 5-aminosalicylic acid.